Clinical and literature analysis of amphotericin B-associated nephrogenic diabetes insipidus
10.3760/cma.j.cn114015-20240321-00182
- VernacularTitle:两性霉素B相关肾性尿崩症临床及文献病例分析
- Author:
Jie YU
1
;
Nan XU
;
Miao YANG
;
Meng LI
;
Gaoshuang LAN
;
Zhengxiang LI
;
Hengjie YUAN
Author Information
1. 天津医科大学总医院药剂科，天津 300052
- Publication Type:Journal Article
- Keywords:
Amphotericin B;
Diabetes insipidus, nephrogenic;
Liposomes;
Antifungal agents
- From:
Adverse Drug Reactions Journal
2024;26(8):467-473
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features, management, and prognosis of amphotericin B (AmB)-associated nephrogenic diabetes insipidus (NDI).Methods:The diagnosis and treatment process of a patient with AmB-related NDI who was admitted to the General Hospital of Tianjin Medical University was reported, and the main clinical data of the patient and related cases such as gender, age, primary disease, medication, NDI occurrence, treatment and outcome collected from CNKI, Wanfang Medical, and VIP databases, PubMed, Web of Science, and ScienceDirect (up to August 22, 2023) were analyzed descriptively.Results:A total of 11 patients were included in the analysis, including 7 males and 4 females, with an average age of 41 years, ranging from 12 to 66 years. The correlation between AmB and NDI was probable in 7 cases and possible in 4 cases. The time from the beginning of medication to the occurrence of NDI was 3 days to 3 weeks, and the urine volume was 3.8-10.8 L/d. Among the 11 patients, 6 patients had hypokalemia and 5 patients had elevated serum creatinine; 9 patients did not stop using AmB due to their conditions, the intervention plans were described in details in 4 patients and AmB treatments were completed after symptomatic treatments, 7 patients were cured or improved, and 2 patients died. Among the 2 patients who stopped taking the medication, 1 patient showed significant improvement in symptoms and resumed using AmB without recurrence; the other case was improved after stopping the medication, but relapsed after resuming use without stopping the medication, and the patient died from the primary disease.Conclusions:During the use of AmB, close attention should be paid to the occurrence of NDI. After occurrence of NDI, most patients can continue taking the AmB and have a good prognosis after symptomatic treatments.
